Sentence examples for i formulation from inspiring English sources

Part I: Formulation and simulation characteristics.

An integrated limiting equilibrium approach for design of reinforced soil retaining structures part I – formulation.

Previously, a novel nocathiacin I formulation for intravenous administration has been successfully developed and its aqueous solubility is greatly enhanced for clinical application.

The development has been mainly on three fronts: (i) formulation of interfacial forces (ii) closure problem for the eddy viscosity and (iii) modelling of the correlations arising out of Reynolds averaging procedure.

In this paper we extend our recently published theory [Anand, L., Ames, N. M., Srivastava, V., Chester, S. A., 2009. A thermo-mechanically-coupled theory for large deformations of amorphous polymers. Part I: formulation.

Two key strategies are emphasized: (i) formulation of the governing ordinary differential equations (ODE) for dynamic stiffnesses and their derivatives and the solution of the ODE problem by standard ODE solvers; and (ii) establishment of mesh generation rules for the two problems.

The hydrophilic solvents such as triethyl citrate, polyethylene glycol 400 (PEG400) and propylene glycol are used in smaller quantities in lipid-based Type-III formulations to aid in self-emulsification through a phenomenon called "dispersion and stranding".

Out of these four systems, Type-II formulations are named as self-emulsifying drug delivery systems (SEDDS, coarse emulsions) and Type-III formulations are named as self-microemulsifying drug delivery systems (SMEDDS, microemulsions) due to their ability to form instantaneous emulsions with minimal energy input.

Incorporating BSA in the IGF-I formulations decreased the initial burst from 80%to20%0%, while using uncapped PLGA rather than capped decreased the initial burst of TGF-β1 from 60% to 0% upon hydration.

The aim of this study was to test the in vitro efficacy of four povidone iodine (PVP-I) formulations against EBOV: 4 % PVP-I skin cleanser; 7.5 % PVP-I surgical scrub; 10 % PVP-I solution; and 3.2 % PVP-I and 78%% alcohol solution.

In addition, we explored whether MVA would be a suitable test virus to assess virucidal activity against EBOV, which is also an enveloped virus, by comparing the in vitro virucidal efficacy of the PVP-I formulations against MVA with their efficacy against EBOV.